

THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI 2022

Sabrina Chiloiro, M.D, PhD

**Catholic University of
the Sacred Heart Rome, Italy**



2022 AWARD WINNER

Sabrina Chiloiro, MD and PhD is a clinical and translational endocrine researcher at the Pituitary Unit of the Endocrinology Department at the Catholic University of the Sacred Heart, in Rome.

She graduated in Medicine and Surgery with full honors in 2011 at the Catholic University of the Sacred Heart, in Rome, discussing a degree thesis on the prognostic role of the proliferative index in pituitary adenomas, that was awarded at the “6th Edition of Italian Hypothalamus Pituitary Meeting”, in 2012.

In 2012 and 2013 she followed a post-graduated research fellow on “New technology in molecular medicine” at the Padua University. She trained in Endocrinology and started her research projects, at the Pituitary Unit of the Catholic University of the Sacred Heart from 2013 to 2018, mentoring by Prof. Laura De Marinis. During the whole of 2019 she was Research Fellow at the Pituitary Unit of the Endocrinology Department. She received the PhD degree in 2021 conducting a research project on primary and immunotherapy induced hypophysitis.

Her research covers a broad range of translational and clinical topics on pituitary disease including secreting and not secreting pituitary neoplasia, acromegaly, prolactinoma, hypophysitis, hypopituitarism and bone fragility.

She is active in international collaborative studies and phase I/II/III clinical trials on acromegaly, hypopituitarism, and neuroendocrine tumors.

Dr Chiloiro has authored on peer-reviewed original articles, reviews, editorials, commentaries, book chapters and abstracts, and has been a speaker at national and international congresses. She is highly involved in teaching medical students, residents, and physician assistant students.

Dr Chiloiro Sabrina was honored by the European Society of Endocrinology with the Young Investigator Award for the research “Effect of Pegvisomant and somatostatin receptor ligands on the risk of vertebral fractures in patients with acromegaly” in 2017.